Chronic inflammation persists when acute stimulus cannot be eliminated or resolution fails, involving macrophage infiltration, angiogenesis, and fibroblast activation. Repeated cycles of injury and repair drive tissue remodeling and organ dysfunction.
Compare acute and chronic morphology: macrophages vs. neutrophils, lymphocytic infiltration, granuloma formation in tuberculosis, and fibrosis in silicosis and asbestos exposure.
Chronic inflammation does not require a long duration of acute inflammation—it can begin immediately if the inciting stimulus persists. Fibrosis is not purely restorative; excessive collagen deposition impairs function.
From acute inflammation, you know the classic sequence: tissue injury triggers vascular changes, neutrophils flood the site, they engulf debris, and resolution restores normal architecture. Acute inflammation has a defined endpoint — once the stimulus is removed and the debris is cleared, resolution factors like lipoxins and resolvins shut the process down. Chronic inflammation is what happens when that endpoint is never reached. The stimulus persists, resolution fails, or the immune system mistakes self for foreign — and the inflammatory machinery runs continuously, damaging the very tissue it was meant to protect.
The cellular character of chronic inflammation is fundamentally different from the acute phase. Neutrophils — the first responders of acute inflammation — are largely absent. Instead, the infiltrate is dominated by macrophages and lymphocytes. Macrophages in chronic inflammation are not the short-lived cells of acute response; they are long-lived, tissue-resident cells continuously secreting cytokines (TNF-α, IL-1β, IL-6), proteases, and reactive oxygen species. Lymphocytes, particularly T helper cells, amplify the macrophage response through interferon-gamma and provide adaptive immune specificity if an antigen is driving the process. This macrophage-lymphocyte partnership is the cellular hallmark of chronic inflammation.
A signature morphological feature is granuloma formation. When macrophages cannot destroy a pathogen or foreign body — Mycobacterium tuberculosis is the classic example, but silica crystals and schistosome eggs also trigger this — they fuse into multinucleated giant cells and surround the offending agent in a walled-off aggregate of activated macrophages called an epithelioid granuloma. The granuloma attempts containment when elimination fails. In tuberculosis, the center of the granuloma undergoes caseous necrosis — a crumbly, cheese-like necrotic core — as the immune response destroys tissue in an attempt to starve the bacteria of oxygen and nutrients. Granulomatous inflammation is therefore not just inflammation but a recognition that normal clearance mechanisms have reached their limits.
The most tissue-destructive consequence of chronic inflammation is fibrosis. As macrophages secrete TGF-β, fibroblasts are recruited and activated to deposit collagen. In the short term this is reparative — it fills gaps where functional tissue has been destroyed. But in chronic inflammation, collagen deposition is sustained and progressive, replacing functional parenchyma with scar tissue. In the liver, portal fibrosis and bridging fibrosis lead to cirrhosis, destroying the hepatocyte mass needed for metabolism. In the lung, pulmonary fibrosis progressively stiffens alveolar walls, reducing gas exchange area. The key insight is that fibrosis is not a side effect of a "strong" immune response — it is the direct result of unresolved inflammatory signaling driving chronic fibroblast activation. The more chronic the inflammation, the more extensive the fibrosis, and the more permanent the functional loss.
Understanding chronic inflammation also reframes many common diseases. Atherosclerosis is not merely a plumbing problem of cholesterol accumulation — it is a chronic inflammatory process in arterial walls, driven by oxidized LDL activating endothelial cells and macrophages that become foam cells. Type 2 diabetes involves chronic low-grade inflammation in adipose tissue and the liver, driven by lipid overload and macrophage infiltration, that impairs insulin signaling. Even many cancers arise in the context of chronic inflammation — H. pylori–driven gastric inflammation precedes gastric cancer; HBV/HCV-driven hepatic inflammation precedes hepatocellular carcinoma. The tissue damage, fibrosis, and abnormal proliferative signals generated by decades of chronic inflammation create fertile ground for malignant transformation. Chronic inflammation is therefore not a localized pathological curiosity but a common pathway underlying some of the most prevalent diseases of modern medicine.